Signaling Pathways in Cancer Metabolism: Mechanisms and Therapeutic Targets

Overview

Journal Signal Transduct Target Ther

Specialties Cell Biology
Pharmacology

Date 2023 May 10

PMID 37164974

Authors

Mengshu You

ZhuoLin Xie

Nan Zhang

Yixuan Zhang

Desheng Xiao

Shuang Liu

Wei Zhuang

Lili Li

Yongguang Tao

Affiliations

Soon will be listed here.

Abstract

A wide spectrum of metabolites (mainly, the three major nutrients and their derivatives) can be sensed by specific sensors, then trigger a series of signal transduction pathways and affect the expression levels of genes in epigenetics, which is called metabolite sensing. Life body regulates metabolism, immunity, and inflammation by metabolite sensing, coordinating the pathophysiology of the host to achieve balance with the external environment. Metabolic reprogramming in cancers cause different phenotypic characteristics of cancer cell from normal cell, including cell proliferation, migration, invasion, angiogenesis, etc. Metabolic disorders in cancer cells further create a microenvironment including many kinds of oncometabolites that are conducive to the growth of cancer, thus forming a vicious circle. At the same time, exogenous metabolites can also affect the biological behavior of tumors. Here, we discuss the metabolite sensing mechanisms of the three major nutrients and their derivatives, as well as their abnormalities in the development of various cancers, and discuss the potential therapeutic targets based on metabolite-sensing signaling pathways to prevent the progression of cancer.

Citing Articles

Bridging epigenomics and tumor immunometabolism: molecular mechanisms and therapeutic implications.

Xie X, Liu W, Yuan Z, Chen H, Mao W Mol Cancer. 2025; 24(1):71.

PMID: 40057791 PMC: 11889836. DOI: 10.1186/s12943-025-02269-y.

Plant-derived terpenoids modulating cancer cell metabolism and cross-linked signaling pathways: an updated reviews.

Pandey P, Verma M, Sanghvi G, R R, Joshi K, V K Naunyn Schmiedebergs Arch Pharmacol. 2025; .

PMID: 40019530 DOI: 10.1007/s00210-025-03937-y.

Diagnostic and Therapeutic Implications of the SUMOylation Pathway in Acute Myeloid Leukemia.

Chatzikalil E, Arvanitakis K, Filippatos F, Diamantopoulos P, Koufakis T, Solomou E Cancers (Basel). 2025; 17(4).

PMID: 40002226 PMC: 11853134. DOI: 10.3390/cancers17040631.

Tonsil-Derived Mesenchymal Stem Cell-Derived Small Extracellular Vesicles (sEVs) Restore Myo-Inositol Production in LPS-Treated Skeletal Muscle.

Cho K, Kim Y, Woo S, Ryu K Tissue Eng Regen Med. 2025; .

PMID: 39998743 DOI: 10.1007/s13770-025-00709-w.

Microbes, macrophages, and melanin: a unifying theory of disease as exemplified by cancer.

Berg S, Berg J Front Immunol. 2025; 15:1493978.

PMID: 39981299 PMC: 11840190. DOI: 10.3389/fimmu.2024.1493978.

References

Richon V, Garcia-Vargas J, Hardwick J . Development of vorinostat: current applications and future perspectives for cancer therapy. Cancer Lett. 2009; 280(2):201-10. DOI: 10.1016/j.canlet.2009.01.002. View

Serhan C . Pro-resolving lipid mediators are leads for resolution physiology. Nature. 2014; 510(7503):92-101. PMC: 4263681. DOI: 10.1038/nature13479. View

Mandal C, Ghosh-Choudhury T, Yoneda T, Ghosh Choudhury G, Ghosh-Choudhury N . Fish oil prevents breast cancer cell metastasis to bone. Biochem Biophys Res Commun. 2010; 402(4):602-7. PMC: 2993881. DOI: 10.1016/j.bbrc.2010.10.063. View

Lu M, Zhu W, Wang X, Tang J, Zhang K, Yu G . ACOT12-Dependent Alteration of Acetyl-CoA Drives Hepatocellular Carcinoma Metastasis by Epigenetic Induction of Epithelial-Mesenchymal Transition. Cell Metab. 2019; 29(4):886-900.e5. DOI: 10.1016/j.cmet.2018.12.019. View

Furtado C, Luciano M, da Silva Santos R, Furtado G, Moraes M, Pessoa C . Epidrugs: targeting epigenetic marks in cancer treatment. Epigenetics. 2019; 14(12):1164-1176. PMC: 6791710. DOI: 10.1080/15592294.2019.1640546. View

Zhang W, Wang W, Xu M, Xie H, Pu Z . GPR43 regulation of mitochondrial damage to alleviate inflammatory reaction in sepsis. Aging (Albany NY). 2021; 13(18):22588-22610. PMC: 8507289. DOI: 10.18632/aging.203572. View

Lynch T, Ferrer C, Jackson S, Shahriari K, Vosseller K, Reginato M . Critical role of O-Linked β-N-acetylglucosamine transferase in prostate cancer invasion, angiogenesis, and metastasis. J Biol Chem. 2012; 287(14):11070-81. PMC: 3322861. DOI: 10.1074/jbc.M111.302547. View

Kim J, Chen J . regulation of peroxisome proliferator-activated receptor-gamma activity by mammalian target of rapamycin and amino acids in adipogenesis. Diabetes. 2004; 53(11):2748-56. DOI: 10.2337/diabetes.53.11.2748. View

Chen L, Zhang Q, Xiao Y, Fang Y, Xie X, Nan F . Phosphodiesters as GPR84 Antagonists for the Treatment of Ulcerative Colitis. J Med Chem. 2022; 65(5):3991-4006. DOI: 10.1021/acs.jmedchem.1c01813. View

10.

Nakanishi S, Cleveland J . Targeting the polyamine-hypusine circuit for the prevention and treatment of cancer. Amino Acids. 2016; 48(10):2353-62. PMC: 5573165. DOI: 10.1007/s00726-016-2275-3. View

11.

Kefas B, Comeau L, Erdle N, Montgomery E, Amos S, Purow B . Pyruvate kinase M2 is a target of the tumor-suppressive microRNA-326 and regulates the survival of glioma cells. Neuro Oncol. 2010; 12(11):1102-12. PMC: 3098027. DOI: 10.1093/neuonc/noq080. View

12.

Choudhary C, Weinert B, Nishida Y, Verdin E, Mann M . The growing landscape of lysine acetylation links metabolism and cell signalling. Nat Rev Mol Cell Biol. 2014; 15(8):536-50. DOI: 10.1038/nrm3841. View

13.

Mendoza M, Er E, Blenis J . The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation. Trends Biochem Sci. 2011; 36(6):320-8. PMC: 3112285. DOI: 10.1016/j.tibs.2011.03.006. View

14.

Lee B, Mahmud I, Marchica J, Derezinski P, Qi F, Wang F . Integrated RNA and metabolite profiling of urine liquid biopsies for prostate cancer biomarker discovery. Sci Rep. 2020; 10(1):3716. PMC: 7048821. DOI: 10.1038/s41598-020-60616-z. View

15.

Clark R, McDonough P, Swanson E, Trost S, Suzuki M, Fukuda M . Diabetes and the accompanying hyperglycemia impairs cardiomyocyte calcium cycling through increased nuclear O-GlcNAcylation. J Biol Chem. 2003; 278(45):44230-7. DOI: 10.1074/jbc.M303810200. View

16.

Chan J, Kulke M . Targeting the mTOR signaling pathway in neuroendocrine tumors. Curr Treat Options Oncol. 2014; 15(3):365-79. PMC: 4147239. DOI: 10.1007/s11864-014-0294-4. View

17.

Offermanns S, Colletti S, Lovenberg T, Semple G, Wise A, IJzerman A . International Union of Basic and Clinical Pharmacology. LXXXII: Nomenclature and Classification of Hydroxy-carboxylic Acid Receptors (GPR81, GPR109A, and GPR109B). Pharmacol Rev. 2011; 63(2):269-90. DOI: 10.1124/pr.110.003301. View

18.

Zibelman M, Wong Y, Devarajan K, Malizzia L, Corrigan A, Olszanski A . Phase I study of the mTOR inhibitor ridaforolimus and the HDAC inhibitor vorinostat in advanced renal cell carcinoma and other solid tumors. Invest New Drugs. 2015; 33(5):1040-7. PMC: 4573837. DOI: 10.1007/s10637-015-0261-3. View

19.

Bar-Peled L, Chantranupong L, Cherniack A, Chen W, Ottina K, Grabiner B . A Tumor suppressor complex with GAP activity for the Rag GTPases that signal amino acid sufficiency to mTORC1. Science. 2013; 340(6136):1100-6. PMC: 3728654. DOI: 10.1126/science.1232044. View

20.

Taggart A, Kero J, Gan X, Cai T, Cheng K, Ippolito M . (D)-beta-Hydroxybutyrate inhibits adipocyte lipolysis via the nicotinic acid receptor PUMA-G. J Biol Chem. 2005; 280(29):26649-52. DOI: 10.1074/jbc.C500213200. View